Gonococcal infection

Gonococcal infection is a sexually transmitted bacterial infection caused by Neisseria gonorrhoeae, an organism with tropism for columnar epithelium that primarily infects the mucosa of the urogenital system, rectum, pharynx, and conjunctiva ^[1][2].

Infection localizes to mucosal surfaces lined by columnar epithelium in the urogenital tract, rectum, pharynx, and conjunctiva ^[1]. Anorectal and pharyngeal gonococcal infections very often take an asymptomatic course, which complicates diagnostic ascertainment and shapes the observed morbidity statistics ^[1]. Natural infection induces a robust Th17-mediated inflammatory response with a large influx of neutrophils and inflammatory cytokines, while Th1- and Th2-mediated responses and antibody titers remain low and short-lived, reflecting the pathogen's capacity to evade host immunity ^[2].

According to WHO estimates cited in the source literature, approximately 87 million new cases of gonorrhea were registered in 2016 among individuals aged 15-49 years, and the number of new gonorrhea cases has been increasing steadily in many countries ^[1]. N. gonorrhoeae is widespread globally, and the substantial contribution of men who have sex with men, migrants, commercial sex workers, and ethnic minorities to propagation is documented in the literature ^[1]. Undetected cervical infection is highlighted as a driver of complications such as pelvic inflammatory disease and infertility, and the asymptomatic profile of anorectal and pharyngeal disease further affects the statistical picture of morbidity ^[1].

Gonococcal infection is transmitted sexually, with N. gonorrhoeae colonizing mucosal sites including the urogenital tract, rectum, pharynx, and conjunctiva following exposure ^[1]. Asymptomatic carriage at anorectal and pharyngeal sites facilitates ongoing spread because infected individuals may be unaware of their infection ^[1].

Primary prevention is reported as unsuccessful, and there is currently no specific vaccine against N. gonorrhoeae, with only one gonococcal-specific candidate having entered clinical trials while several others remain at the preclinical stage ^[2]. Real-world evidence indicates that gonorrhea case counts are reduced among recipients of Neisseria meningitidis group B vaccines containing outer membrane vesicles, although the first randomized trial of such an OMV-containing MenB vaccine did not demonstrate statistically significant vaccine efficacy against N. gonorrhoeae ^[2]. The steady rise in morbidity in groups with risky sexual behavior reinforces the need for prevention programs targeted to these populations ^[1].

1. 1 Ufimtseva MA et al. [The contemporary world trends in epidemiology of gonococcal infection: The publications review]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2021 May. PMID: 34190475. doi: 10.32687/0869-866X-2021-29-3-451-455. PubMed: https://pubmed.ncbi.nlm.nih.gov/34190475/
2. 2 Ruiz García Y et al. Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context. J Infect Dis. 2024 Oct 16. PMID: 38819303. doi: 10.1093/infdis/jiae289. PubMed: https://pubmed.ncbi.nlm.nih.gov/38819303/